Reviewer’s report

Title: Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naive or switching for simplification HIV-infected patients.

Version: 1
Date: 5 December 2013
Reviewer: José-Ramón Blanco

Reviewer’s report:

The major concern are: the reasons for therapy-switching (virologic failure, previous toxicity,...). Which were the main causes of treatment interruption?. Did you had missing data?. How many patients died during the follow-up?. How many lost of follow-up?. A high number of patients on treatment with EFV were IDU (only 6 with STR). Could some of the interruptions be related to methadone use?. Finally, the comparison in the subgroup analysis of STR could be limited by the number of patients with abacavir plus lamivudine backbone (n=42).

This study would benefit from focusing on unique aspects that let them a unique contribution to the literature. For example, which was the outcome of patients over 50 years?.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Consulting work for Abbott Laboratories, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV Healthcare, I have received compensation for lectures from Abbott Laboratories, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV Healthcare, as well as payments for development of educational presentations for Gilead Sciences and Bristol-Myers Squibb.